BioDelivery Sciences International (BDSI) : During the past 4 weeks, traders have been relatively bearish on BioDelivery Sciences International (BDSI), hence the stock is down -1.49% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -0.91% relative to the S&P 500. The 4-week change in the price of the stock is -1.62% and the stock has fallen -0.41% in the past 1 week.
The stock has recorded a 20-day Moving Average of 7.11% and the 50-Day Moving Average is 3.16%.The 200 Day SMA reached 28.54%. BioDelivery Sciences International, Inc. is up 0.41% in the last 3-month period. Year-to-Date the stock performance stands at -49.27%.
BioDelivery Sciences International (NASDAQ:BDSI): The stock opened in the green at $2.45 on Friday, but the bulls found it difficult to push the prices higher. The stock reached a high of $2.49 and a low of $2.3811 for the day. The stock did not find buyers even at the lows and closed at $2.43 recording a loss of -0.82%. 381,548 shares exchanged hands during the trading day. The stock had closed at $2.45 in the previous days trading.
BioDelivery Sciences International, Inc. is a specialty pharmaceutical company. The Company develops and commercializes, either on its own or in partnerships with third parties, applications of approved therapeutics to address unmet medical needs using drug delivery technologies. The Company develops pharmaceutical products aimed principally in the areas of pain management and addiction. The Companys products and certain of its product candidates utilize the BioErodible MucoAdhesive (BEMA) drug delivery technology, a small, erodible polymer film for application to the buccal mucosa (the lining inside the cheek). The Companys United Sates Food and Drug Administration (FDA) approved product, ONSOLIS (fentanyl buccal soluble film), as well as its approved product BUNAVAIL (buprenorphine and naloxone buccal film) and its product candidate, BELBUCA utilize its BEMA technology.